ATNM INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ATNM To Contact Him Directly To Discuss Their Options

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Iomab-B BLA application and its clinical trial data [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses exceeding $75,000 in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [2][6]. Group 2: Allegations Against Actinium - The complaint alleges that Actinium and its executives made false and misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA, based on data from the Sierra Trial [4]. - It is claimed that the additional analyses provided to the FDA were unlikely to satisfy the agency's guidelines, leading to a probable refusal to review or approve the BLA [4]. Group 3: Impact on Stock Price - Following the revelation of the need for an additional clinical trial to support the BLA filing, Actinium's stock price dropped significantly, falling $3.69, or nearly 60%, to close at $2.48 on August 5, 2024 [5].